Radcliffe Capital Management’s NKGen Biotech, Inc. Common Stock NKGN Stock Holding History

Radcliffe Capital Management’s Portfolio NKGN Stock Details NKGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-641,462	Closed	-$6.63M	–	494
2023 Q2	$6.63M	Sell	641,462 -55,493	-8%	-$568K	0.56%	42
2023 Q1	$7.06M	Buy	696,955 +9,155	+1%	+$92.4K	0.44%	56
2022 Q4	$6.84M	Buy	687,800 +85,000	+14%	+$840K	0.22%	117
2022 Q3	$5.88M	Hold	602,800	–	–	0.14%	218
2022 Q2	$5.85M	Hold	602,800	–	–	0.13%	214
2022 Q1	$5.85M	Buy	602,800 +2,800	+0.5%	+$27.1K	0.13%	174
2021 Q4	$5.8M	Hold	600,000	–	–	0.15%	129
2021 Q3	$5.81M	Buy	+600,000	New	+$5.85M	0.17%	101

Other funds holding NKGN

Meteora Capital Boca Raton, Florida $1.21B AUM 13.69% 1-Year Est. Return

RCM

Rivernorth Capital Management West Palm Beach, Florida $2.1B AUM 2.15% 1-Year Est. Return

SIM

Sandia Investment Management Boston, Massachusetts $40.1M AUM 14.58% 1-Year Est. Return

Diametric Capital Boston, Massachusetts $948M AUM 47.49% 1-Year Est. Return

Periscope Capital Toronto, Ontario, Canada $1.14B AUM 6.91% 1-Year Est. Return

KIM

Karpus Investment Management Pittsford, New York $3.48B AUM 10.49% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return

AIMCA

Alberta Investment Management Corp (AIMCo) Edmonton, Alberta, Canada $17.9B AUM 27.56% 1-Year Est. Return

MTCM

Mint Tower Capital Management Amsterdam, Netherlands $871M AUM 8.61% 1-Year Est. Return

WCMNY

Westchester Capital Management (New York) Valhalla, New York $2.04B AUM 31.03% 1-Year Est. Return

Radcliffe Capital Management's NKGN Position: Q3 2023 in Review

Radcliffe Capital Management sold out of NKGen Biotech, Inc. Common Stock (NKGN) in Q3 2023, closing a stake of 641,462 shares — an estimated $6.63M sold.

Radcliffe Capital Management first reported a position in NKGN in Q3 2021 and held it in 8 quarters. The position peaked at $7.06M in Q1 2023. 13 funds tracked by Wall St. Rank hold NKGN as of Q3 2023.

Radcliffe Capital Management reported no remaining NKGen Biotech, Inc. Common Stock position as of Q3 2023 after selling out during the quarter.
Radcliffe Capital Management sold 641,462 NKGen Biotech, Inc. Common Stock shares in Q3 2023, an estimated $6.63M.
Radcliffe Capital Management first reported a position in NKGen Biotech, Inc. Common Stock in Q3 2021 and held it in 8 quarters.
Radcliffe Capital Management's NKGen Biotech, Inc. Common Stock position peaked at $7.06M in Q1 2023.
13 funds tracked by Wall St. Rank held NKGen Biotech, Inc. Common Stock as of Q3 2023.

Based on Radcliffe Capital Management's 13F filing for Q3 2023, filed 14 Nov 2023.